Exact Sciences Inc. (EXAS) - Gross Profit Ratio

Official company branding of Exact Sciences Corp (EXAS)

Stable demand for non-invasive diagnostics and insurance coverage for Cologuard create a solid business foundation for Exact Sciences (EXAS). Historical gross margins illustrate this efficiency, with 69.70 representing the current metric. High-margin screening tests that reduce mortality support profit growth, while strategic partnerships with oncology centers and biopharmaceutical companies accelerate the expansion of Exact Sciences (EXAS) in the field of early cancer detection.

EXAS (Exact Sciences Corporation) Gross Profitability history from 07/04/2022 to 04/04/2026

Financial and market metric breakdowns for exactsciences.com (EXAS)

- price and consensus price forecast:
Fundamental valuation:EXAS Exact Sciences Corp
Core merchandise of Exact Sciences

Gross margin measures production efficiency by determining the profit share remaining after covering direct costs. By analyzing the gross margin chart on GURU.Markets, an investor assesses the ability of Exact Sciences (EXAS) management to pass inflation onto customers. This metric is sensitive to the cost of services and reflects the business's fundamental margin of safety. The stability of this indicator is supported by the optimization of a unique biosample collection system and high-speed laboratory processing.